Using tissue monitoring to improve surgery for brain tumors
Feasibility of Aspirate Tissue Monitoring in Neuro-oncological Surgery
This study is testing a new tool that helps surgeons find and remove brain tumor tissue more effectively during surgery for patients with high-grade gliomas.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Kuopio University Hospital Academic / other |
| Locations | 3 sites (Kuopio, Northern Savonia and 2 other locations) |
| Trial ID | NCT06740097 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of an aspirate tissue monitor (ATM) during neurosurgery for high-grade gliomas. The ATM detects cancerous tissue from suction waste in near real-time, providing audible feedback to surgeons when tumor-related fluorescence is identified. By integrating this technology with 5-aminolevulinic acid (5-ALA) fluorescence-guided surgery, the trial aims to enhance tumor removal efficiency, reduce blood loss, and minimize the risk of leaving residual tumor tissue. The study is multicenter and controlled, involving several prominent hospitals.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are scheduled for surgical resection of suspected high-grade gliomas.
Not a fit: Patients who are children, pregnant, prisoners, or intellectually disabled will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective surgical outcomes and improved survival rates for patients with high-grade gliomas.
How similar studies have performed: While the use of fluorescence-guided surgery has shown promise, the specific application of aspirate tissue monitoring in this context is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient admitted to neurosurgery department for surgical resection of a suspected high-grade glioma * Patients aged 18 years old or older * Informed consent obtained Exclusion Criteria: * Patient belongs to the following vulnerable groups: children, pregnant, prisoners or intellectually disabled
Where this trial is running
Kuopio, Northern Savonia and 2 other locations
- Kuopio University Hospital — Kuopio, Northern Savonia, Finland (Recruiting)
- Tampere University Hospital — Tampere, Pirkanmaa, Finland (Recruiting)
- Oslo University Hospital — Oslo, Norway (Not_yet_recruiting)
Study contacts
- Principal investigator: Antti-Pekka Elomaa, Docent — Kuopio University Hospital
- Study coordinator: Sami Puustinen, PhD
- Email: sami.puustinen@marginum.com
- Phone: +358442190767
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.